| Drug Name |
Romidepsin |
| Drug ID |
BADD_D01964 |
| Description |
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. |
| Indications and Usage |
For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XH02 |
| DrugBank ID |
DB06176
|
| KEGG ID |
D06637
|
| MeSH ID |
C087123
|
| PubChem ID |
5352062
|
| TTD Drug ID |
D0L7LC
|
| NDC Product Code |
63323-926; 53183-4026; 54893-0083; 0703-4004; 68254-0009; 59572-984 |
| UNII |
CX3T89XQBK
|
| Synonyms |
romidepsin | L-Valine, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (S-(E))- | FK228 | FR 901228 | FR-901228 | FR901228 | istodax |
